Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Why Merck KGaA, Darmstadt, Germany Paid Sutro Biopharma. See Also: BMY Approval of Zeposia for UC

June 1, 2021 0

Sutro Biopharma Receives Milestone Payment from Merck KGaA, Darmstadt, Germany Sutro Biopharma (STRO) announced that it …

Amgen: FDA Approves LUMAKRAS™, the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

May 31, 2021 0

Amgen Announced FDA Approval of LUMAKRAS™ Amgen (AMGN) announced the news about the FDA approval of LUMAKRAS™ …

GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

May 27, 2021 0

GlaxoSmithKline and Vir Biotechnology are Granted an EUA for Sotrovimab GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) …

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

May 26, 2021 0

Aptevo Therapeutics Inc in the News Aptevo Therapeutics Inc (APVO) has positive results from the Phase …

Prilenia Therapeutics’ Pridopidine Product for Huntington’s and Lou Gehrig’s Diseases Could be Promising

May 25, 2021 0

Prilenia Therapeutics Prilenia Therapeutics is a clinical-stage biotech company. The firm’s leader, Michael Hayden, MD, PhD., …

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

May 25, 2021 0

Recursion Pharmaceuticals Product REC-163964 Recursion Pharmaceuticals Inc (RXRX) announced the initiation of an investigational new drug …

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

May 21, 2021 0

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc (ANVS), a clinical-stage drug platform company. This …

Reata Pharmaceuticals: Good News from the FDA Regarding Omaveloxolone for Friedreich’s Ataxia

May 19, 2021 0

Reata Pharmaceuticals Good News Reata Pharmaceuticals (RETA) announced it received a communication from the Division of …

An Important Agreement Between Bristol-Myers Squibb and Agenus

May 18, 2021 0

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb (BMY) and Agenus (

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

May 17, 2021 0

Sanofi and GlaxoSmithKline COVID-19 Vaccine Sanofi (SNY) and GlaxoSmithKline (GSK

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

May 14, 2021 0

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in …

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

May 13, 2021 0

Compugen Updated Trial Data Updated data from COM701 Phase 1 combination and monotherapy studies to be …

Cassava Sciences Awarded NIH Grant. See Also: Intellia Therapeutics Presentations at the 24th ASGCT Meeting

May 12, 2021 0

Cassava Sciences Awarded NIH Research Grant for Simufilam Cassava Sciences (SAVA) announced that it has been …

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

May 10, 2021 0

Sutro Biopharma Inc Sutro Biopharma (STRO) is a clinical-stage drug discovery, development and manufacturing company. Its …

ADC Therapeutics: Moving from a Development-Stage Firm to a Revenue-Generating Firm

May 7, 2021 0

ADC Therapeutics First Quarter Financial Results and Business Updates ADC Therapeutics SA (ADCT) is a commercial-stage biotechnology …

Editas Medicine: Business Highlights and Financial Results Reported

May 5, 2021 0

Editas Medicine Reporting Editas Medicine (EDIT) reported business highlights and financial results for the first quarter …

Vir Biotechnology

May 4, 2021 0

Prohost Portfolio PLUS #5 Vir Biotechnology Vir Biotechnology (VIR) combines cutting-edge technologies with immunologic insights to …

Gilead Sciences Conference Call Information. See Also: Compugen Announcements

April 29, 2021 0

Gilead Sciences First-Quarter 2021 Financial Results Conference Call Info Gilead Sciences (GILD) management will host a …

AstraZeneca: Tagrisso Recommended for Marketing Authorization in the EU for Early Stage EGFRm NSCLC

April 27, 2021 0

AstraZeneca: Tagrisso for Adult Patients with Early-Stage EGFRm NSCLC... AstraZeneca (AZN): Tagrisso (osimertinib) has been recommended …

Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus

April 27, 2021 0

Sanofi and AstraZeneca MELODY Trial Results for Nirsevimab In March 2017, Sanofi (SNY) and AstraZeneca (

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Why Merck KGaA, Darmstadt, Germany Paid Sutro Biopharma. See Also: BMY Approval of Zeposia for UC

Amgen: FDA Approves LUMAKRAS™, the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

Prilenia Therapeutics’ Pridopidine Product for Huntington’s and Lou Gehrig’s Diseases Could be Promising

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Reata Pharmaceuticals: Good News from the FDA Regarding Omaveloxolone for Friedreich’s Ataxia

An Important Agreement Between Bristol-Myers Squibb and Agenus

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Cassava Sciences Awarded NIH Grant. See Also: Intellia Therapeutics Presentations at the 24th ASGCT Meeting

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

ADC Therapeutics: Moving from a Development-Stage Firm to a Revenue-Generating Firm

Editas Medicine: Business Highlights and Financial Results Reported

Vir Biotechnology

Gilead Sciences Conference Call Information. See Also: Compugen Announcements

AstraZeneca: Tagrisso Recommended for Marketing Authorization in the EU for Early Stage EGFRm NSCLC

Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus